NCT07091747View on ClinicalTrials.gov

Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

December 12, 2025

Study Completion Date

December 12, 2025

Conditions
Alzheimer Disease (AD)
Interventions
OTHER

Cannabis 50 mg of CBD and 5 mg of THC

Cannabis 50 mg of CBD and 5 mg of THC

Trial Locations (1)

85870-650

Universidade Federal da Integração Latino-Americana, Foz do Iguaçu

All Listed Sponsors
collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico

OTHER_GOV

lead

Federal University of Latin American Integration

OTHER